SPOTLIGHT: DeCode launches genetic trial

Iceland's DeCode Genetics has launched a closely watched Phase III trial of DG031 to prevent heart attacks. The company will track the results of 3,400 African-American subjects who have a genetic variant linked to heart attacks. Report

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.